Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) is the NASDAQ pre-market leader this morning on news that its subcutaneous SGI-110 interim phase I.II MDS and AML data demonstrated differentiated PK profile and good tolerability, as well as a preliminary promising complete responses in heavily pre-treated acute myelogenous leukemia patients enrolled in the Phase 1 segment of the trial.
The randomized Phase 1/2 first-in-human dose escalation study had 66 patients enrolled who were previously treated as of March 28, 2012.
In the data, two of the seven evaluable refractory AML patients with adequate hypomethylation with no prior resistance to hypomethylating agents showed a complete response and one patient showed partial response.
The pharmacokinetic data suggests delivery of decitabine by SGI-110 achieves high decitabine exposure. It also showed a longer half life and a potent dose-dependent hypomethylation induction in the daily regimen.
Shares are trading higher by 13.6% at $2.09 in the pre-market and the 52-week trading range is $1.51 to $3.35. The market cap before the news was a mere $171 million.
JON C. OGG
This may seem unusual, but did you know some credit cards can actually help you get OUT of debt faster? It’s true. Every day thousands of Americans are waking up to the secret: using a ‘0% Intro APR‘ card.
Here’s how it works. You find a card that offers a 0% balance transfer feature (not all do, but theses ones are top picks from the editors at FinanceBuzz). Next, you transfer your current balance to this new card, securing ZERO interest payments for the intro term, then you use the savings to pay off debt faster. The math is straight forward, and can save you hundreds, thousands, even tens of thousands of dollars if used correctly. Find the right card for you by clicking here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
